Targeting KRAS with reversible inhibitors

Nat Rev Drug Discov. 2022 May;21(5):338. doi: 10.1038/d41573-022-00062-w.
No abstract available

MeSH terms

  • Humans
  • Mutation
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Proto-Oncogene Proteins p21(ras)* / genetics
  • Signal Transduction*

Substances

  • KRAS protein, human
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins p21(ras)